Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective, epithelial, and neural tissues. Therapeutically, it is used as a visco-supplement for joints, an ophthalmic surgical aid, or a topical hydrating agent.
## Primary Indications
* **Intra-articular:** Management of pain in osteoarthritis (OA) of the knee in patients who have failed conservative non-pharmacologic therapy and simple analgesics.
* **Ophthalmic:** Surgical aid for cataract extraction, IOL implantation, and corneal transplant.
* **Dermatological:** Skin hydration and wound healing.
## Adult Dosing
* **Intra-articular (Knee OA):**
* *High molecular weight (e.g., Sodium Hyaluronate):* 20 mg/2 mL injection administered intra-articularly into the knee once weekly for 3–5 weeks.
* *Hylan G-F 20:* 16 mg/2 mL injection administered once weekly for 3 weeks.
* *Single-injection products (e.g., Hymovis, Durolane):* 60 mg (3 mL) once per treatment cycle.
* **Ophthalmic/Topical:** Highly product-dependent; refer to specific manufacturer labeling.
## Pediatric Dosing
Safety and efficacy have not been established for intra-articular injection in pediatric patients. Use in pediatric dermatology is generally considered safe but lacks standardized systemic or site-specific dosing guidelines.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific adjustments provided; systemic absorption is minimal with intra-articular use.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Active joint infection or skin disease/infection in the area of the injection site.
* Known hypersensitivity to avian proteins (if the product is derived from avian sources).
## Adverse Effects
* **Common:** Arthralgia, injection site pain, joint swelling or effusion, stiffness.
* **Serious:** Pseudoseptic reaction (acute inflammatory response), localized hypersensitivity reactions.
## Key Drug Interactions
No clinically significant systemic drug-drug interactions documented due to local application/injection. Avoid concurrent intra-articular disinfectants (e.g., quaternary ammonium salts), which may precipitate hyaluronan.
## Monitoring
* Monitor for post-injection "flare" (acute joint pain/swelling) within 24–48 hours.
* Evaluate joint function and pain relief response at 3–6 months post-injection cycle.
## Clinical Pearls
* **Efficacy:** Results may be delayed; symptomatic relief is typically observed 4–8 weeks post-injection.
* **Technique:** Sterile technique is mandatory to avoid iatrogenic septic arthritis.
* **Dosing Variation:** Always verify the specific brand/product, as molecular weights and dosing frequencies vary significantly between hyaluronic acid derivatives.
* **Cost-Effectiveness:** Clinical literature regarding the long-term benefit of viscosupplementation compared to corticosteroids or standard physical therapy remains debated.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by institution and patient-specific factors. Always consult the latest FDA-approved prescribing information or your local formulary guidelines before prescribing or administering medication.
